上半年生物技术收入在上半年增长了9.84％ - 年龄

Source: Shanghai Securities News ・ China Securities Securities Securities News China Securities Network On the night of August 20, Biotech published a six -month report by 2025. In the first half, the company achieved an operational gain of 442 million yuan, 9.84% more than the previous year, mainly due to the aggressive expansion of its market Adalimumab (Geril) (Gerli®) (Gerli®)与去年相比，（Gerli®）（Gerli®）注射（Shirui®）不断增加。在报告期间，与去年同期相比，我们的总收入，净收入和收入没有下降1.12亿元，1.12亿元和99,3.69亿元人民币，这主要是由于运营收入的增加和报告期间的最高R＆D费用。在报告期间，与去年同期相比，我们的OPE Activity rativos产生的净现金流量下降了624.4444亿元，这主要是由于从本报告期间出售和提供商品的服务收到的现金增加。D并减少了R＆D D的支出。该公司遵守“创新仅是生命”的概念，并遵守创新促进的开发策略，它正在努力开发新一代的创新药物和生物仿制药，以治疗肿瘤，自身免疫性疾病，心血管疾病，心血管疾病，ephththalmology and Ophthalmology and ophthalmology and ophthalmology and ophamology and ophamology and ophseases and to and肿瘤。 As of the dissemination date of this report, the company has five products in the market. Four of these products are approved by the NMPA. Gerli® (Adalimumab), Pubecizumab, Schreli® (Tocizumab) and Bethanin® (Bevibatid Citrate); FDA批准了三种产品：Tofience®（Tocizumab），Avzivi®（bevacizumab）和Starjemza®（Uminomab）。这三种产品均由EMA：BAT1806（Tocizumab），Avzivi®（bevacizumab）和Usymro®批准。 A product is approved by Anvisa: Bevyx® (Bevacizumab). In addition, the company has presented marketing authorization applications for many products, and many are in the stages of clinical and prec统一研究。 （Lyo Yuwen） 官方NINA Finance帐户 24-最新信息和财务视频的流离失所，以及扫描QR码以关注更多粉丝（Sinafinance）